Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > COMMENTARY
COMMENTARY
- From "Replacement" to "Addition": Prescription Form
January 23, 2006
- Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (I) －２－
January 23, 2006
- Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (I) －１－
January 23, 2006
- A Happy Year 2006 to Japanese Pharmaceutical Stocks!
January 23, 2006
- Industry Should Insist on Brand Average Market Price Principle
January 16, 2006
- The Bottom of the Tornado
January 16, 2006
- ＜New Year's commentary＞Looking at the Pharma Industry Backward from 2009 -1- Sugio Seko, President Pharma Marketing Survey Research Laboratory (December, 2005)
January 9, 2006
- ＜New Year's commentary＞Looking at the Pharma Industry Backward from 2009 -2- Sugio Seko, President Pharma Marketing Survey Research Laboratory (December, 2005)
January 9, 2006
- Schrodinger's Cat
December 12, 2005
- Top Wholesalers Cut Costs to Offset Declines in Gross Profits
December 5, 2005
- Importance of Framing
November 21, 2005
- A Cluster of Diseases - Metabolic Syndrome: Reflecting Aging Society
November 7, 2005
- A Cluster of Diseases - Metabolic Syndrome:Reflecting an Aging Society -1-
October 31, 2005
- Commentary 2005 Will Be "Year 1" of Japanese Drug Industry Reorganization
October 17, 2005
- COMMENTARY 2 articles
October 10, 2005
- COMMENTARY 6 articles
September 19, 2005
- Where Will the Japanese Pharmaceutical Industry Drift? - From "The Sky Is the Limit" to the Abyss -
August 29, 2005
- COMMENTARY 5 articles
August 8, 2005
- 2 Rosai Hospitals Start Prescriptions by the Generic Name
July 25, 2005
- COMMENTARY 6 articles
July 25, 2005
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…